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Background and Aims.Moodmay have an important role in the natural history of inflammatory bowel disease (IBD). However, the
impact of antidepressant use on prognosis is unknown. We aimed to address this in a longitudinal study in a referral population.
Methods.We collected demographic data, clinical disease activity andmood using validated questionnaires, and antidepressant use
at baseline. Longitudinal disease activity was defined by disease flare or need for glucocorticosteroids, escalation ofmedical therapy,
hospitalisation, or intestinal resection. We compared rates of these over a minimum period of 2 years according to antidepressant
use at baseline. Results. In total, 331 patients provided complete data, of whom 54 (15.8%) were taking an antidepressant at study
entry.Older age, female gender, and abnormalmood scoreswere associatedwith antidepressant use.During longitudinal follow-up,
there was a trend towards lower rates of any of the four endpoints of IBD activity of interest in patients with abnormal anxiety scores
at baseline and who were receiving an antidepressant (42.3% versus 64.6%, P = 0.05). Based on univariate Cox regression analysis,
there was a trend towards lower rates of escalation of medical therapy among patients receiving antidepressants at baseline (hazard
ratio (HR) = 0.59; 95% confidence interval (CI) 0.35-1.00, P = 0.05). None of the differences observed persisted after multivariate
Cox regression.Conclusions. Antidepressants may have some beneficial effects on the natural history of IBD, but larger studies with
longer follow-up are required. Whether these effects are limited to patients with abnormal mood remains uncertain.
1. Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic
inflammatory organic disorders of the gastrointestinal (GI)
tract of unknown aetiology, which may arise from dysreg-
ulation of both the innate and adaptive immune systems,
leading to persistent and damaging inflammation of the intes-
tine. Conventional therapies for inflammatory bowel dis-
ease (IBD) include glucocorticosteroids, 5-aminosalicylates,
immunosuppressants, and biological therapies [1–7], with the
aim of treatment being to induce remission of GI inflamma-
tion and prevent future disease relapse.
Patientswith IBDappear to be at increased risk of exhibit-
ing mood disorders, such as anxiety or depression, compared
with healthy individuals [8–12]. However, whether this is a
consequence of, or an etiological factor in, GI inflammation
remains uncertain. In people with functional GI disorders,
such as irritable bowel syndrome, longitudinal studies suggest
that there is an increased likelihood of asymptomatic people
who demonstrate anxiety or depression at baseline develop-
ing GI symptoms de novo [13]. This raises the possibility that
coexistent anxiety or depression in patients with IBD, partic-
ularly if unrecognised or untreated, may have a deleterious
effect on the natural history of IBD.
Evidence to support a role of abnormal mood in sub-
sequent IBD activity comes mainly from animal models.
Studies have demonstrated that inmousemodels of quiescent
colitis, inducing depression leads to reactivation ofGI inflam-
mation [14] but that this can be prevented by preadminis-
tration of antidepressants [15]. There is also limited evidence
in humans to suggest that acute psychological stress induces
proinflammatory cytokine production in both the serum and
the mucosa of IBD patients [16]. Studies that have examined
the effect of psychological comorbidity on the natural history
of IBD suggest that patients with coexistent mood disorders
have higher rates of disease relapse, escalation of therapy,
and IBD-related surgery than patients with IBD without
psychological disorders [17–20]. Despite this, the benefit of
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treatments, such as psychological therapies or antidepres-
sants, which target mood abnormalities in patients with IBD
is uncertain. A systematic review and meta-analysis of 14
randomised controlled trials (RCTs) of cognitive behavioural
therapy, hypnotherapy, and other psychological interventions
failed to demonstrate any effect on subsequent disease activity
[21]. However, none of the included trials recruited only
patients with psychological comorbidity. Another systematic
review examining the effect of antidepressants on the course
of IBD identified 15 studies [22], but the majority of these
were case series or case reports. There were few longitudinal
studies and only one small pilot RCT of fluoxetine in CD [23],
which appeared to be of no benefit in terms of maintenance
of disease remission.
This is an important issue, as patients with quiescent IBD
may be at a lower risk of subsequent relapse of disease activity
if coexisting mood disorders are identified and treated. This
could lead to a more benign disease course, with fewer
episodes of flares of disease activity and reductions in treat-
ment escalation, hospitalisation, or surgery. There is, there-
fore, a need for epidemiological studies that examine the
effects of antidepressants on the course of IBD in a setting
that is generalisable to the type of patients with IBD seen in
secondary care. We have therefore conducted a longitudinal
follow-up study examining these issues in a large number
of patients with IBD. Our a priori hypothesis was that there
would be lower rates of, and longer time of onset to, objective
markers of subsequent disease activity among those patients
prescribed antidepressants at baseline.
2. Materials and Methods
2.1. Participants and Setting. Individuals recruited into a
previous cross-sectional survey were included in this longitu-
dinal follow-up study [24, 25]. All patients had an established
radiological, histological, or endoscopic diagnosis of CD or
UC and were aged ≥16 years at the time of baseline recruit-
ment. Exclusion criteria were an inability to understand
written English, a diagnosis of IBD-unclassified, and anyone
with an end ileostomy or colostomy, due to the difficulties
in assessing disease activity indices in these patients. Partici-
pants were followed up after aminimumperiod of 2 years had
elapsed from initial recruitment. The longitudinal follow-up
study was approved by the local research ethics committee in
September 2014 (REC ref: 12/YH/0443), and data collection
continued until June 2017. Study findings were reported in
accordance with the STROBE guidelines for observational
studies [26].
2.2. Data Collection and Synthesis. Date of recruitment into
the original cross-sectional survey, demographic data, type of
IBD, medication use for both IBD and non-IBD-related dis-
ease, and data concerning anxiety, depression, somatisation,
and quality of life data were recorded at baseline, as described
in the original cross-sectional survey [24, 25].
2.2.1. Definition of Disease Activity, Anxiety or Depression,
and Somatisation. At baseline assessment, a combination of
disease activity indices (the Harvey-Bradshaw index (HBI)
for CD [27] and the simple clinical colitis activity index
(SCCAI) for UC [28]) were utilised. Clinical remission was
defined as a score <5 for both CD and UC, as has been
recommended by previous investigators [29, 30].
Anxiety and depression data were collected using the
hospital anxiety and depression scale (HADS) [31]. This 14-
item questionnaire consists of seven questions screening for
the presence of anxiety symptoms and seven for depression
symptoms, with a 4-point response for each item, ranging
from 0 to 3. The total HADS score ranges from a minimum
of 0 to a maximum of 21 for both anxiety and depression.
Severity was categorised, according to total HADS score,
into normal (total HADS depression or anxiety score 0-7),
borderline normal (8-10), and abnormal (≥11) as previously
recommended [31].
Somatisation data were collected using the patient health
questionnaire-15 (PHQ-15), which is derived from the val-
idated full PHQ [32]. Individuals were asked to rate the
severity of 15 predefined symptoms as “not bothered at all”
(scored as 0), “bothered a little” (scored as 1), or “bothered a
lot” (scored as 2). Therefore the total PHQ-15 score ranges
from a minimum of 0 to a maximum of 30. Somatisation
severity was categorised, using the total PHQ-15 score, into
high (total PHQ-15≥15), medium (10-14), low (5-9), andmin-
imal (≤4) levels of somatisation severity, again as previously
recommended [32].
2.2.2. Antidepressant Use. Use of antidepressants was cap-
tured at the baseline visit. We recorded the regular prescrip-
tion of any of the following drugs at study entry: selec-
tive serotonin reuptake inhibitors (SSRIs) including fluoxe-
tine, fluvoxamine, paroxetine, sertraline, citalopram, escitalo-
pram; tricyclic antidepressants (TCAs) including amitripty-
line, nortriptyline, imipramine, clomipramine, desipramine,
doxepin, or dosulepin; serotonin and noradrenaline reuptake
inhibitors (SNRIs) including venlafaxine and duloxetine;
tetracyclic antidepressants including mirtazapine; and atyp-
ical antidepressants, such as trazodone.
2.2.3. Longitudinal Objective Assessment of IBD Activity.
Objective assessment of disease activity during longitudinal
follow-up was made by detailed case note review by a sole
investigator (DJG), blinded to the baseline questionnaire
data. The case notes of each of the patients included at base-
line were assessed for the following four clinical endpoints,
with the date of each endpoint recorded, where applicable:
documented glucocorticosteroid prescription or a flare of
disease activity identified by physician’s global assessment;
escalation of medical therapy due to uncontrolled disease
activity, as judged by a physician’s global assessment; hospi-
talisation secondary to objectively confirmed IBD activity;
and intestinal resection. All these decisions were made as per
usual care, as this was a noninterventional study conducted
in routine clinical practice. Escalation of medical therapy in
response to therapeutic drug monitoring, but in the absence
of inflammatory activity, was not included as an endpoint,
nor was surgical intervention for isolated perianal Crohn’s
disease.
Canadian Journal of Gastroenterology and Hepatology 3
2.3. Statistical Analysis. Baseline demographic, disease-relat-
ed, and psychological data for all participants were compared
between those taking and not taking antidepressants at study
entry. Due to multiple comparisons we considered a 2-
tailed P value of <0.01 to be statistically significant for these
analyses. Proportions of patients experiencing the occurrence
of one, or any, of the four objective markers of IBD activity
during longitudinal follow-up were then compared between
those patients taking an antidepressant at baseline and those
who were not. We planned to perform subgroups analyses
according to type of antidepressant used (SSRI, TCA, SNRI,
or tetracyclic) as well as presence or absence of anxiety
and/or depression at baseline, to assess whether these had
any impact on the association between antidepressant use and
IBD activity during longitudinal follow-up. We compared
proportions in all these analyses using a𝜒2 test for categorical
variables and an independent samples t-test for continuous
data.
We then performed univariate Cox regression analysis to
examine the effect of antidepressant use on IBD activity dur-
ing longitudinal follow-up for all patients, and according to
presence or absence of anxiety and/or depression at base-
line. Independent predictors of the occurrence of any of
the objective disease activity outcomes of interest were
then determined by performing multivariate Cox regression
analysis to control for antidepressant use, as well as all other
baseline data. The results of these analyses were expressed as
hazard ratios (HR) with 95% confidence intervals (CI). As
our hypothesis that there would be lower rates of objective
markers of IBD activity among those patients prescribed
antidepressants at baseline was defined a priori, for these
analyses we considered a 2-tailed P value of <0.05 to be sta-
tistically significant. All statistical analyses were performed
using SPSS forWindows version 22.0 (SPSS Inc., Chicago, IL,
USA).
3. Results
In total, 54 (15.8%) of 342 patients were taking an antide-
pressant at study entry. Of these, 32 (59.3%) were taking an
SSRI, 17 (31.5%) a TCA, two (3.7%) an SNRI, two (3.7%) both
an SSRI and a TCA, and one (1.9%) trazodone. Older age
and female gender were both associated with antidepressant
use, and there was a trend towards a higher body mass index
(BMI) among those using antidepressants (Table 1). Patients
with abnormal HADS anxiety or depression scores and those
with high somatisation levels were more likely to be taking an
antidepressant at baseline (P < 0.001).
3.1. Effect of Antidepressant Use on Subsequent IBD Activity.
Of these 342 patients, 331 (96.8%) provided complete follow-
up data for longitudinal IBD activity after case note review
and were included in subsequent analyses. In all, 142 (42.9%)
of 331 patients had a flare of disease activity or required glu-
cocorticosteroid therapy during the 2-year follow-up period.
Furthermore, 137 (41.4%) patients underwent escalation of
medical therapy in response to uncontrolled disease activ-
ity. In terms of hospitalisation and intestinal resection, 43
(13.0%) and 19 (0.6%) patients experienced these endpoints
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Figure 1: Cumulative hazard for escalation of medical therapy in
response to uncontrolled IBD between patients receiving or not
receiving antidepressants.
of interest, respectively. There were no differences in pro-
portions of patients experiencing a flare of disease activity
or glucocorticosteroid use, need for escalation of therapy,
hospitalisation, intestinal resection, or any of these endpoints
according to use of antidepressants at baseline (Table 2).
Limiting our analyses for flare of disease activity or requiring
glucocorticosteroid therapy or escalation of medical therapy
to only those who were in clinical remission at baseline did
not affect our findings—9 (39.1%) of 23 patients receiving
antidepressants experienced a flare of disease activity or
needed a prescription for glucocorticosteroids versus 49
(32.0%) of 153 not receiving (P = 0.50); 7 (30.4%) of 23
patients receiving antidepressants required escalation of ther-
apy versus 60 (39.2%) of 153 nor receiving (P = 0.42).
Based on univariate Cox regression analysis, there was a
trend towards lower rates of escalation of medical therapy
among patients receiving antidepressants at baseline, com-
pared with those who were not (HR = 0.59; 95% CI 0.35 to
1.00, P = 0.05) (Table 3, Figure 1), but this was no longer the
case based on multivariate Cox regression controlling for all
baseline data.
We performed subgroup analyses according to pres-
ence or absence of anxiety and/or depression at baseline
(Table 2). There was a trend towards lower rates of escalation
of therapy among those with either abnormal anxiety or
depression scores at baseline and who were receiving an
antidepressant, compared with those with either abnormal
anxiety or depression scores at baseline but who were not
receiving an antidepressant (25.5% versus 46.6%, P = 0.06).
There were significantly lower rates of escalation of therapy
among patients with abnormal anxiety scores at baseline and
who were receiving an antidepressant, compared with those
with abnormal anxiety scores at baseline but who were not
receiving an antidepressant (23.1% versus 47.7%, P = 0.03).
Finally there was a trend towards lower rates of any of the
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Figure 2: Cumulative hazard for escalation of medical therapy
in response to uncontrolled IBD between patients with abnormal
anxiety or depression scores at baseline receiving or not receiving
antidepressants.
four endpoints of IBD activity of interest in patients with
abnormal anxiety scores at baseline and who were receiv-
ing an antidepressant, compared with those with abnormal
anxiety scores at baseline but who were not receiving an
antidepressant (42.3% versus 64.6%, P = 0.05). Based on
univariate Cox regression analysis, again there was a trend
towards lower rates of escalation of medical therapy among
patients with either abnormal anxiety or depression scores at
baseline who were receiving antidepressants, compared with
those with either abnormal anxiety or depression scores at
baseline but who were not (HR = 0.47; 95% CI 0.21 to 1.05,
P = 0.07) (Table 3) (Figure 2). However, this was no longer
the case based on multivariate Cox regression.
3.2. Effect of SSRI Use on Subsequent IBD Activity. In total,
33 (61.1%) of all 54 patients taking an antidepressant at
baseline were receiving an SSRI. There were no significant
differences in the proportions of patients prescribed an
SSRI experiencing one, or any, of the endpoints of interest,
compared with those who were not (Table 4).
Based on univariate Cox regression analysis, there was
a significantly lower rate of escalation of medical therapy
among patients receiving SSRIs at baseline, compared with
those whowere not (HR= 0.47; 95%CI 0.24 to 0.93, P = 0.03)
(Table 3) (Figure 3). This was no longer observed based on
multivariate Cox regression.
Due to a reduced number of individuals taking SSRIs we
were unable to perform subgroup analyses according to the
presence of only abnormal anxiety scores, or only abnormal
depression scores, at baseline. In the remaining analyses,
there were trends towards higher rates of intestinal resection
among patients with normal anxiety and depression scores
at baseline who were taking SSRIs (15.4% versus 3.9%, P
= 0.06) and lower rates of hospitalisation among patients
with either abnormal anxiety or depression scores at baseline
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Figure 3: Cumulative hazard for escalation of medical therapy in
response to uncontrolled IBD between patients receiving or not
receiving SSRIs.
receiving SSRIs (0% versus 16.4%, P = 0.05) (Table 4). Based
on both univariate (Table 3) and multivariate Cox regression
analysis, there were no significant differences in rates of
flare or glucocorticoid prescription, escalation of medical
therapy, hospitalisation, or intestinal resection among SSRI
users according to presence or absence of abnormal anxiety
or depression scores at baseline.
4. Discussion
Results from univariate Cox regression analysis in this
longitudinal study, adjusted for total duration of follow-up
among all individuals, suggest a trend towards lower rates
of subsequent escalation of medical therapy among patients
with IBD receiving antidepressants at baseline, and this
persisted when only those patients with abnormal anxiety
or depression scores at study entry were considered in the
analysis. Similar findings were observed when only those
using SSRIs at baseline were considered in the analysis.
However, none of these associations remained statistically
significant based on multivariate Cox regression analysis.
Our findings, although interesting, should be considered
as preliminary only, and larger studies with longer follow-
up, or rigorous RCTs, which are powered to examine this
issue specifically, will be required before the true effect of
antidepressant use on objective disease endpoints in patients
with IBD is known.
We obtained longitudinal disease activity outcome data
for a cohort of 331 patients with IBD. The observational
design and the use of a secondary care population mean that
our findings are likely to be generalisable to the majority of
patients with IBD seen outside specialist centres. Our use of
validated questionnaires to assess for the presence of anxiety
[31], depression [31], or somatisation [32] at baseline is a
further strength. We controlled for differences in duration
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of follow-up between those receiving, or not receiving,
antidepressants at baseline and all other baseline data, using
multivariate Cox regression. Finally, objective longitudinal
disease activity assessment data were collected blinded to
baseline disease activity and psychological data, therefore
eliminating researcher confirmation bias.
Weaknesses include the sample size and length of follow-
up. Based on multivariate Cox regression analysis, there were
no statistically significant differences observed in rates of
any of the objective markers of disease activity according
to antidepressant use at baseline, despite the fact that the
absolute proportion of patients reaching these endpointswere
generally lower among those taking antidepressants at base-
line, particularly among those with abnormal anxiety and/or
depression scores at baseline. This suggests that if our sample
size had been larger, or the duration of follow-up longer,
some of these comparisons may have become statistically
significant. Alternatively, there may be a true beneficial effect
that was lost when other factors were controlled for in our
multivariate analysis.This could be due to either confounding
or a loss of time contributed to the analysis from individuals
with missing data for these demographic characteristics.
Our assessment of psychological well-being was based on
questionnaire responses at a single point in time, and our
use of HADS scores as a marker of anxiety or depression
could be criticised as, although these are widely used, their
psychometric properties have been challenged [33]. Although
we collected disease activity endpoints based on objectively
defined criteria, there is the possibility that some of these
endpoints, such as escalation of therapy, were reached based
on symptom reporting alone, rather than true inflammatory
activity. Due to the low event rate for some of the longitudinal
disease activity outcomes, we chose not to present data on
IBD patients dichotomised into those with UC and CD, or
according to the use of antidepressant subclasses, other than
SSRIs. Finally, use of antidepressants at baseline was classified
according to a documented current prescription for the drugs
of interest, but whether patients were actually adherent to
their antidepressant therapy is uncertain. In addition, we
did not record the discontinuation or commencement of
antidepressant drugs during follow-up and therefore cannot
exclude some misclassification of patients.
Due to the chronicity of their disease and the required
shifts in coping and self-management skills over time, it is not
surprising that patients with IBD are at increased risk ofmen-
tal health disorders, yet previous studies have demonstrated
that these coexistent psychological problems are often under-
treated [34]. Undertreatment of mental health disorders can
lead to long-term disability and a stigma against seeking
treatment [35, 36]. Most IBD specialists have little formal
training in the detection andmanagement of such psycholog-
ical comorbidities. This lack of training, combined with the
potential hesitancy of many patients to report psychological
symptoms, may influence therapy options. Although our
study demonstrated that patients with abnormal anxiety or
depression scores and those with high somatisation levels
were more likely to be taking an antidepressant at baseline,
the prevalence of abnormal anxiety scores, abnormal depres-
sion scores, and high somatisation scores in patients not
receiving antidepressant therapy was also relatively high at
24.2%, 7.7%, and 20.7%, respectively.
Decreasing potential long-term sequelae by minimising
the inflammatory burden in IBD patients is an important
treatment strategy. There is some evidence, from studies in
both animals and humans with IBD, to suggest that psycho-
logical comorbidity can trigger inflammatory activity [14, 16].
Furthermore, patients with IBD are at increased risk of psy-
chological comorbidity, particularly depression and anxiety
[37].Thus, pharmacological therapy for mood disorders may
have the potential to alter the natural history of CD and UC.
Limited data, to date, have suggested improvements inmood,
inflammatory activity, and quality of life with antidepressant
therapy [23, 38]. Our own longitudinal follow-up data did
not show any statistically significant differences in the pro-
portion of patients experiencing endpoints consistent with
inflammatory activity, according to use of antidepressants at
baseline. However, the absolute proportions reaching these
endpoints were generally lower among those prescribed
antidepressants, particularly when only those with abnormal
anxiety or depression scores were considered in the analysis.
Mechanisms of any beneficial effect of antidepressant
drugs on the course of IBD are uncertain. Some antidepres-
sants, like amitriptyline, appear to have both pain modify-
ing properties [39] and direct effects on proinflammatory
cytokines that may arise via actions on the nuclear factor-
𝜅B and nitric oxide pathways, which are implicated in the
pathogenesis of IBD [40]. The former may explain the trend
towards a reduction in escalation of therapy we observed,
although given that this was also observed when only patients
taking SSRIs, which have less in the way of analgesic
effects [39], were considered, this seems unlikely. Therefore,
antidepressant therapy may indeed have a beneficial effect
on inflammatory activity. However, differentiating the true
inflammatory burden in a symptomatic patient with IBD and
coexistent mood disorder can be difficult, as the available
symptom scoring systems cannot confirm the true origin of
symptoms, and patients with IBD with psychological comor-
bidity may be more likely to report GI symptoms in general
[24, 25]. As a result patients with mood disorders and who
were on antidepressants in our study may potentially have
been less likely to be offered, or indeed accept, a glucocor-
ticosteroid prescription, a step-up in therapy, hospitalisation,
or surgery.
In summary, our longitudinal follow-up study demon-
strated lower rates of some objective markers of disease activ-
ity among patients with IBD receiving antidepressants and
SSRIs, at baseline, particularly among those with abnormal
anxiety or depression scores at baseline. However, none were
statistically significant based on multivariate Cox regression.
Further observational studies or RCTs with longer follow-
up, which are powered to examine this issue specifically, will
be required before the true effect of antidepressant use on
disease activity in patients with CD and UC is known.
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